John Patrick Shannon Jr. - 17 Nov 2023 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
President and Chief Operating Officer
Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
17 Nov 2023
Net transactions value
+$50,400
Form type
4
Filing time
17 Nov 2023, 17:58:32 UTC
Previous filing
01 Feb 2023
Next filing
31 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Purchase $50,400 +30,769 +2.2% $1.64 1,408,575 17 Nov 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6250 to $1.6400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Remarks:

President and Chief Operating Officer